Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.60 |
| ▸ | JAK1 | P23458 | 5/20 | 0.60 |
| ▸ | TYK2 | P29597 | 5/20 | 0.60 |
| ▸ | JAK3 | P52333 | 5/20 | 0.60 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12724673 | 0.86 | JAK2 (0.56) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL13498228 | 0.85 | JAK2 (0.56) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL1634420 | 0.83 | JAK2 (0.55) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL1634968 | 0.80 | JAK2 (0.63) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL12724448 | 0.80 | JAK2 (0.71) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL1635098 | 0.80 | JAK2 (0.74) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL1635082 | 0.80 | JAK2 (0.52) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL1634109 | 0.80 | JAK2 (0.67) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL17529314 | 0.77 | JAK2 (0.55) | JAK2JAK1TYK2JAK3TNIK | |
| SCHEMBL1633256 | 0.76 | JAK2 (0.67) | JAK2JAK1TYK2JAK3TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | JAK2 1352/4885JAK1 2248/4885TYK2 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.